Eli Lilly and Co. has signed agreements with private investors Care Capital and NovaQuest Capital to establish BioCritica, Inc., a new, privately held biotechnology company. Based in central Indiana, BioCritica will initially focus on the continued U.S. development and commercialization of Lilly’s severe sepsis drug Xigris, with plans to build a portfolio of hospital-based critical care medicines. BioCritica will acquire rights to Xigris the U.S. and will receive the rights to potentia...